Poliovirus excretion among persons with primary immune deficiency disorders: Summary of a seven-country study series

Journal of Infectious Diseases

Volumn 210, Issue , 2014, Pages S368-S372

  Li, Li ^a   Ivanova, Olga ^b   Driss, Nadia ^c   Tiongco Recto, Marysia ^d   Da Silva, Rajiva ^e   Shahmahmoodi, Shohreh ^f   Sazzad, Hossain M S ^g   Mach, Ondrej ^h   Kahn, Anna Lea ^h   Sutter, Roland W ^h  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

^c PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^d UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^e Medical Research Institute Colombo   (Sri Lanka)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

OPV; poliovirus excretion; primary immune deficiency; vaccine derived polioviruses

Indexed keywords

ADULT; BANGLADESH; CHINA; FECES ANALYSIS; FEMALE; HUMAN; IMMUNE DEFICIENCY; IRAN; MAJOR CLINICAL STUDY; MALE; PHILIPPINES; POLIOMYELITIS VIRUS; REVIEW; RUSSIAN FEDERATION; SRI LANKA; TUNISIA; VIRUS DETECTION; VIRUS EXCRETION; VIRUS SHEDDING; ADOLESCENT; AFRICA; ASIA; CHILD; COMPLICATION; IMMUNOCOMPROMISED PATIENT; INFANT; ISOLATION AND PURIFICATION; POLIOMYELITIS; PRESCHOOL CHILD; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICA; ASIA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; MALE; POLIOMYELITIS; POLIOVIRUS; RUSSIA; VIRUS SHEDDING; YOUNG ADULT;

EID: 84906560673     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu065     Document Type: Review

References (34)

1. Sutter RW, Kew O, Cochi SL, Aylward BA. Poliovirus Vaccine-live. In: Vaccines, 6th edition. Philadephia, PA: Elsevier, Inc., 2013; 598-645
2. Terry L. The association of cases of poliomyelitis with the use of type 3 oral poliomyelitis vaccines.Washington, DC: US Department of Health, Education, and Welfare 1962.
3. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296:356-9.
4. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59:587-635.
5. Notar angelo L, Casanova J-L, Conley ME, et al. Primary immunodeficiency diseases: An update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol 2006; 117:883-96.
6. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92:34-48.
7. Llobet MP, Soler-Palacin P, Detkova D, Hernandez M, Caragol I, Espanol T. Common variable immunodeficiency: 20-yr experience at a single centre. Pediatr Allergy Immunol 2009; 20:113-8.
8. Sutter R, Prevots D. Vaccine-Associated paralytic poliomyelitis among immunologically abnormal persons. Infect Medicine 1994; 11:426, 429-30, 435-8.
9. Kew OM, Sutter RW, Nottay BK, et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol 1998; 36:2893-9.
10. Yang C-F, Chen H-Y, Jorba J, et al. I ntratypic Recombination among lineages of Type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol 2005; 79:12623-34.
11. Nathanson N, Kew OM. From emerg ence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010; 172:1213-29.
12. Cases of Wild Poliovirus by Country and Year. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx. Accessed 09/11/2013.
13. Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med 2010; 362:2360-9.
14. Wassilak S, Pate MA, Wannemuehler K, et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis 2011; 203:898-909.
15. Burns CC, Shaw J, Jorba J, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol 2013; 87 :4907-22.
16. Centers for Disease C, Prevention. Poliovirus infections in four unvaccinated children-Minnesota, August-October 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1053-5.
17. Alexander JP, Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis 2009; 199:391-7.
18. Rhoden E, Liu HM, Wang-Chern SW, Oberste MS. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds. Antiviral Res 2013; 98:186-91.
19. Exploring the Role of Antiviral Drugs in the Eradication of Polio. In: Academies NRCotN, ed. Washington DC, 2006.
20. Organization WH. Acute flaccid paralysis (AFP) surveillance : the surveillance strategy for poliomyelitis eradication. Geneva, 1998 (WHO, ed.
21. Shahmahmoodi S, Parvaneh N, Burns C, et al. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X- linked agammaglobulinemia. Virus Res 2008; 137:168-72.
22. Halsey NA, Pinto J, Espinosa-Rosales F, et al. Search for poliovirus carriers among people with primary immune deficiency diseases in th e United States, Mexico, Brazil and the United Kingdom. Bull World Health Organ 2004; 82:3-8.
23. Modell V, Gee B, Lewis DB, et al. Global study of primary immunodeficiency diseases (PI)-diagnosi s, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res 2011; 51:61-70.
24. Modell F, Puente D, Modell V. From genotype to phenotype. Further studie s measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of primary immunodeficiencies. Immunol Res 2009; 44:132-49.
25. Hull BP, Dowdle WR. Poliovirus surveillance: building the global Polio Laboratory Network. J Infect Dis 1997; 175 (suppl 1):S113-6.
26. World Health Organization. Department of Immunization Vaccines and Biologicals. Polio laboratory manual. 4th ed. Geneva:World Health Organization, 2004.
27. Tiongco-Recto M, Sumpaico MW. Sumpaico, Regina Dionisio-Capulong ea. Prevalence of Prolonged and Chronic Poliovirus Excretion among Persons with Primary Immune Deficie ncy Disorders in the Philippines. Acta Medica Philippina 2012; 46:1-11.
28. de Silva R, Gunasena S, Ratnayake D, et al. Prevalence of prolonged and chronic poliovirus excretion among persons with pri mary immune deficiency disorders in Sri Lanka. Vaccine 2012; 30:7561-5.
29. Driss N, Ben-Mustapha I, Mellouli F, et al. High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies. Clin Vaccine Immunol 2012; 19:1684-9.
30. Sazzad HM, Rainey JJ, Mach O, et al. The feasibility of identifying children with primary immunod eficiency disorders: preparation for the polio post-eradication era in Bangladesh. Vaccine 2012; 30:5396-400.
31. Hammarstrom L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin Exp Immunol 2000; 120:225-31.
32. Rezaei N, Pourpak Z, Aghamohammadi A, et al. Consanguinity in Primary Immunodeficiency Disorders; the Report from Iranian Primary Immunodeficiency Registry. Am J Reprod Immunol 2006; 56:145-51.
33. Reda S, Afifi H, Amine M. Primary Immunodeficiency Diseases in Egyptian Children: A Single-Center Study. J Clin Immunol 2009; 29:343-51.
34. DeVries AS, Harper J, Murray A, et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med 2011; 364: 2316-23.